IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer

NCT04434482 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumours
Small Cell Lung Cancer

Interventions

DRUG: IMP4297(senaparib)

Sponsor

Impact Therapeutics, Inc.